Summit Therapeutics (SMMT) Change in Account Payables (2017 - 2026)

Summit Therapeutics (SMMT) has reported Change in Account Payables for 10 consecutive years, with -$3.9 million the latest figure, recorded in Q2 2026.

• Quarterly Change in Account Payables fell 121.79% year-over-year to -$3.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$89000.0 (down 100.45% YoY) and the FY2025 annual result came in at $15.3 million, up 659.45% from the prior year.
• Change in Account Payables eased to -$3.9 million in Q2 2026 per SMMT's latest filing, from $6.8 million in the prior quarter.
• Over the last five years, Change in Account Payables for SMMT reached as high as $17.9 million in Q2 2025 and fell as low as -$3.9 million in Q2 2026.
• A 5-year average of $1.0 million and a median of $58000.0 in 2023 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2024 — Change in Account Payables sank 1122.56% — and 2026, when it soared 1810.67%.
• Year by year, Change in Account Payables stood at -$2.4 million in 2022, then soared by 71.63% to -$672000.0 in 2023, then jumped by 327.53% to $1.5 million in 2024, then tumbled by 240.29% to -$2.1 million in 2025, then slumped by 82.14% to -$3.9 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$3.9 million, $6.8 million, and -$2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.